Lawmaker Wants Answers About Warning Lag on Sarin Antidote Defects

Diane Barnes, Global Security Newswire
Add to Briefcase
See more stories about...
Diane Barnes, Global Security Newswire
Oct. 2, 2013, 3:02 a.m.

WASH­ING­TON — A U.S. law­maker said a sar­in-an­ti­dote man­u­fac­turer needs to ex­plain why it took over five months longer to in­form ci­vil­ian first re­spon­ders than De­fense De­part­ment of­fi­cials about de­fect­ive syr­inges used to ad­min­is­ter the nerve-agent treat­ment.

A thor­ough un­der­stand­ing of the drug com­pany’s lag in is­su­ing the warn­ings to the dif­fer­ent cus­tom­ers is cru­cial to pre­vent­ing any sim­il­ar no­ti­fic­a­tion delays in the fu­ture about drug de­fects, Rep­res­ent­at­ive An­drew Har­ris (R-Md.) told Glob­al Se­cur­ity News­wire.

The com­pany, a Pf­izer sub­si­di­ary named Me­ridi­an Med­ic­al Tech­no­lo­gies, no­ti­fied ci­vil­ian-emer­gency per­son­nel and whole­sale sup­pli­ers around the United States of the prob­lem­at­ic “DuoDote” syr­inges on Aug. 27, six days after a widely pub­li­cized sar­in-gas strike in Syr­ia’s civil war.

The Pentagon, though, had already been no­ti­fied five months earli­er about de­fects in sim­il­ar syr­inges that it bought from the com­pany to treat troops ex­posed to sar­in.

The Food and Drug Ad­min­is­tra­tion audited Me­ridi­an’s man­u­fac­tur­ing plant earli­er in March, and Pf­izer sub­sequently sus­pen­ded DuoDote pro­duc­tion to in­sti­tute new qual­ity con­trols at the fa­cil­ity, ac­cord­ing to Har­ris’ of­fice.  

Har­ris said a Wall Street Journ­al re­port­er in­formed him months later about the prob­lems, which im­pacted less than 1 per­cent of the ci­vil­ian and mil­it­ary “autoin­ject­or” syr­inges.

The law­maker — an an­es­thesi­olo­gist by train­ing — re­spon­ded by grilling Pf­izer in a let­ter last month on sev­er­al mat­ters tied to the prob­lem syr­inges.

“Me­ridi­an has thor­oughly answered all ques­tions but one: Why did it take al­most six months for the com­pany to no­ti­fy first re­spon­ders of the prob­lem?” Har­ris told Glob­al Se­cur­ity News­wire last week. “That is a ques­tion we must an­swer to make sure the delay does not hap­pen again.”

When quer­ied dir­ectly about the delay in alert­ing ci­vil­ian first re­spon­ders about the de­fect­ive syr­inges, Pf­izer said it needed time “to in­vest­ig­ate the is­sue and im­ple­ment cor­rect­ive ac­tion.”

The com­pany also stressed Wash­ing­ton has played a role in re­spond­ing to de­fects in the ci­vil­ian syr­inges.

“Me­ridi­an, work­ing in co­ordin­a­tion with the [Food and Drug Ad­min­is­tra­tion], and oth­er fed­er­al agen­cies needed to fully un­der­stand the im­plic­a­tions of the prob­lem,” com­pany spokes­man Chris­toph­er Loder told GSN in a state­ment.

The Pf­izer sub­si­di­ary, he said, “no­ti­fied [ci­vil­ian] cus­tom­ers once FDA-ap­proved in­struc­tions and guid­ance could be provided that would sup­port the safe use of the product.

The Food and Drug Ad­min­is­tra­tion, though, said Pf­izer made the de­cision about when to no­ti­fy ci­vil­ian hold­ers of DuoDote about the prob­lems, ac­cord­ing to the con­gress­man’s of­fice.

The later tim­ing of the no­tice to non­mil­it­ary groups might have con­trib­uted to ques­tions among some emer­gency per­son­nel about the avail­ab­il­ity of an­ti­dote for ci­vil­ian vic­tims of a po­ten­tial sar­in strike.

After Me­ridi­an aler­ted first re­spon­ders and oth­ers out­side the Pentagon to the syr­inge de­fects, FDA of­fi­cials ad­vised them to hold on to cer­tain DuoDote stocks for one year longer than their labeled ex­pir­a­tion dates. The nerve-agent an­ti­dote should re­tain its po­tency for the ex­tra time if stored as dir­ec­ted, the agency said in a Sept. 5 let­ter to med­ic­al per­son­nel and bulk re­tail­ers.

The FDA move ap­peared to be an at­tempt to com­pensate for the sus­pen­sion in DuoDote pro­duc­tion. However, some emer­gency re­spon­ders in­dic­ated they had already thrown away DuoDote that had aged out of its ori­gin­al four-year use peri­od. A Sept. 13 Journ­al art­icle notes that Ten­ness­ee au­thor­it­ies pulled lapsed doses of the drug from am­bu­lances be­fore the shelf-life ex­ten­sion in late sum­mer.

Back in Wash­ing­ton, Har­ris as of press time had yet to learn how Pf­izer’s sub­si­di­ary plans to deal with de­fect­ive syr­inges held by ci­vil­ian first re­spon­ders.

However, Loder said Pf­izer plans to “re­place or re­medi­ate” af­fected mil­it­ary an­ti­dote syr­inges that are still “with­in ex­piry,” and ad­ded that “Me­ridi­an ex­pects to reach the same agree­ment with [ci­vil­ian] pur­chasers of DuoDote.”

Har­ris told GSN last week that he planned to keep tabs on how the firm acts on its pledge to qual­ity-check the more than 2 mil­lion sar­in-an­ti­dote doses stocked by the De­fense De­part­ment.

“I be­lieve this prob­lem will be re­solved, and hope­fully it will be re­solved without any­one ever hav­ing to use the de­fi­cient dosage units be­fore they get re­placed,” the con­gress­man said.

Me­ridi­an has already sub­jec­ted 1.1 mil­lion mil­it­ary an­ti­dote syr­inges to phys­ic­al in­spec­tion and dis­carded any that lacked suf­fi­cient an­ti­dote, an un­named mil­it­ary of­fi­cial said in an art­icle by the Pentagon‘s Amer­ic­an Forces Press Ser­vice.

The United States in 2010 and 2012 awar­ded Me­ridi­an more than $250 mil­lion in nerve-gas-an­ti­dote con­tracts for the mil­it­ary alone, the Journ­al re­por­ted. The Obama ad­min­is­tra­tion last week an­nounced a new $60 mil­lion deal for Me­ridi­an to study how an ex­ist­ing sed­at­ive could treat seizures from nerve-agent ex­pos­ure.

What We're Following See More »
BUT WHITE HOUSE MAY USE AGAINST HIM ANYWAY
Ethics Cops Clear Mueller to Work on Trump Case
6 hours ago
THE LATEST

"Former FBI Director Robert Mueller has been cleared by U.S. Department of Justice ethics experts to oversee an investigation into possible collusion between then-candidate Donald Trump's 2016 election campaign and Russia." Some had speculated that the White House would use "an ethics rule limiting government attorneys from investigating people their former law firm represented" to trip up Mueller's appointment. Jared Kushner is a client of Mueller's firm, WilmerHale. "Although Mueller has now been cleared by the Justice Department, the White House may still use his former law firm's connection to Manafort and Kushner to undermine the findings of his investigation, according to two sources close to the White House."

Source:
BUSINESSES CAN’T PLEAD FIFTH
Senate Intel to Subpoena Two of Flynn’s Businesses
7 hours ago
THE LATEST

Senate Intelligence Committee chairman Richard Burr (R-NC) and ranking member Mark Warner (D-VA) will subpoena two businesses owned by former National Security Advisor Michael Flynn. Burr said, "We would like to hear from General Flynn. We'd like to see his documents. We'd like him to tell his story because he publicly said he had a story to tell."

SAYS THEY CHEATED TESTS
Government Sues Fiat Chrysler Over Emissions
8 hours ago
THE LATEST

The government alleges the company put eight “software-based features” on diesel engines in nearly 104,000 Ram pickups and Jeep Grand Cherokees from the 2014 to 2016 model years, which allowed the vehicles to emit fewer pollutants during EPA lab tests than during normal driving conditions.

Source:
KEY ON TRUMPCARE
MacArthur Resigns As Tuesday Group Co-Chair
11 hours ago
BREAKING

Rep. Tom MacArthur resigned Tuesday from his position as co-chair of the Tuesday Group, the House caucus of more moderate GOP members. MacArthur was one of the key engineers in getting an Obamacare replacement plan passed through the House of Representatives, which has caused a rift within the Tuesday Group. "You can't lead people where they don't want to go," MacArthur told POLITICO New Jersey. "I think some people in the group just have a different view of what governing is."

Source:
DETAILS ARE CLASSIFIED
Brennan Saw Russia Intelligence “Worthy” of Investigation
12 hours ago
THE LATEST

At an open hearing of the House Intelligence Committee, former CIA chief John Brennan said he saw information on Trump-Russia contacts that were worth a further look. "Having been involved in many counterintelligence cases in the past, I know what the Russians do. They try to suborn individuals," Brennan said. "And they try to get individuals, including U.S. persons, to act on their behalf, whether wittingly or unwittingly. And I was worried by a number of the contacts that the Russians had with U.S. persons, and so therefore by the time I left office ... I had unresolved questions in my mind."

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login